Cargando…

Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients

High mobility group B1 (HMGB1) is a protein that is released from dying cancer cells in the context of immunogenic cell death (ICD). A recent study performed on patients with head and neck squamous cell carcinomas (HNSCC) reports that a chemoradiotherapy-induced increase in circulating HMGB1 levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroemer, Guido, Kepp, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632107/
https://www.ncbi.nlm.nih.gov/pubmed/34858731
http://dx.doi.org/10.1080/2162402X.2021.2005859
_version_ 1784607693624836096
author Kroemer, Guido
Kepp, Oliver
author_facet Kroemer, Guido
Kepp, Oliver
author_sort Kroemer, Guido
collection PubMed
description High mobility group B1 (HMGB1) is a protein that is released from dying cancer cells in the context of immunogenic cell death (ICD). A recent study performed on patients with head and neck squamous cell carcinomas (HNSCC) reports that a chemoradiotherapy-induced increase in circulating HMGB1 levels predicts favorable outcome, echoing prior studies on neoadjuvant treatment of breast and rectal cancer in which the dynamics of HMGB1 plasma levels also have prognostic value. Hence, a therapy-induced rise in HMGB1 may be interpreted as a clinical sign of ICD and therapeutic response.
format Online
Article
Text
id pubmed-8632107
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-86321072021-12-01 Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients Kroemer, Guido Kepp, Oliver Oncoimmunology Editorial High mobility group B1 (HMGB1) is a protein that is released from dying cancer cells in the context of immunogenic cell death (ICD). A recent study performed on patients with head and neck squamous cell carcinomas (HNSCC) reports that a chemoradiotherapy-induced increase in circulating HMGB1 levels predicts favorable outcome, echoing prior studies on neoadjuvant treatment of breast and rectal cancer in which the dynamics of HMGB1 plasma levels also have prognostic value. Hence, a therapy-induced rise in HMGB1 may be interpreted as a clinical sign of ICD and therapeutic response. Taylor & Francis 2021-11-23 /pmc/articles/PMC8632107/ /pubmed/34858731 http://dx.doi.org/10.1080/2162402X.2021.2005859 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editorial
Kroemer, Guido
Kepp, Oliver
Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
title Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
title_full Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
title_fullStr Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
title_full_unstemmed Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
title_short Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
title_sort radiochemotherapy-induced elevations of plasma hmgb1 levels predict therapeutic responses in cancer patients
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632107/
https://www.ncbi.nlm.nih.gov/pubmed/34858731
http://dx.doi.org/10.1080/2162402X.2021.2005859
work_keys_str_mv AT kroemerguido radiochemotherapyinducedelevationsofplasmahmgb1levelspredicttherapeuticresponsesincancerpatients
AT keppoliver radiochemotherapyinducedelevationsofplasmahmgb1levelspredicttherapeuticresponsesincancerpatients